Biome Australia Ltd · ASX:BIO
Biome Australia — Q2 2025 Earnings Presentation
25 slides from Biome Australia's earnings presentation, Mar 6, 2025
Slide 1: Company Presentation March 2025
Biome Australia al use only March 2025 Company Jan 2024 Strategy Meeting Presentation Blair Vega Norfolk, Founder & Managing Director Company Presentation | March 2025 1
Slide 2: Disclaimer
Biome Australia Disclaimer This presentation and the information contained within it (the This presentation contains forward-looking statements, which may be The recipient must, and agrees with the Company that it will, make its “information”) has been prepared solely for the use and benefit of the i
Slide 3: About Biome Australia
Biome Australia About Biome Australia al use only Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific probiotic products fueled by novel clinical research programs to cement and extend the evidence b
Slide 4: The Microbiome Health Company: Our mission
Biome Australia Group The Microbiome Health Company al use only Our mission To prevent disease, improve health outcomes and quality of life, and make our products accessible to all Company Presentation | March 2025 4
Slide 5: The Microbiome Health Company
Biome Australia Group The Microbiome Health Company al use only Company Presentation | March 2025 55
Slide 6: Activated Probiotics Range
Biome Australia al use only 02. Activated Probiotics Range Company Presentation | March 2025 2025 6
Slide 7: Activated Probiotics
Biome Australia Activated Probiotics al use only Practitioners & Pharmacies CONSUMER BENEFITS 5x more effective delivery — MicrobacTM technology Shelf-stable Clinically documented probiotic strains Company Presentation | March 2025 7
Slide 8: Business Highlights
Biome Australia al use only 01. Business Highlights Company Presentation | March March2025 2025 8
Slide 9: Business Highlights
Biome Australia Biome Business Over 6,000 distribution points (Aus) following successful launch with Priceline Pharmacy Highlights al use only Average shopper ~2.5 units per transaction and 6 visits per year in pharmacy (Terry White Scan data) #1 growth Practitioner-Only brand in Australian Healthca
Slide 10: Business Highlights
Biome Australia Biome Business 1H25 sales revenue of $8.9m (vs $13m FY24) Highlights al use only EBITDA $122k in Q1 & $230k in Q2, an increases of 89% Net profit of $96,228 (excl R&D rebate) for H1 or $433,395(incl R&D rebate) Retail scan sales for two largest pharmacy groups average over 80% growth
Slide 11: Distribution and Sales Model
Biome Australia al use only 03. Distribution and Sales Model Company Presentation | March 2025 11
Slide 12: Training and Education Driven Sales Model - Practitioner Only
Biome Australia Training and Education Driven Sales Model - Practitioner Only al use only Unique Education and Service Model Drives Sales in Australia, UK and NZ Education and Service Support • The Biome sales team is a mix of health qualified practitioner education consultants and territory manager
Slide 13: Vision
Biome Australia al use only 04. Vision 27 Company Presentation March | March 2025 2025 13
Slide 14: Vision: Revenue Growth
Biome Australia Vision 27 Revenue Growth Biome has a three year cumulative sales revenue target of up to $85m. ($75m-$85m for FY25-FY27) ● This represents an increases of 350% on $24m for the three previous years al use only 1. Distribution Growth & Business Development ● Grow the existing 5000* (~4
Slide 15: Vision: Supply Chain and New Brand and Product Range
Biome Australia Vision 27 3. Supply Chain Bring Activated Probiotics to the mainstream market as a ● Identification and viability analysis of a novel probiotic strain that is significant probiotic brand locally and abroad. proprietary to Biome ○ Lactobacillus plantarum BMB18 al use only ○ Positive res
Slide 16: Distribution Growth & Business Development
Biome Australia al use only 03. Distribution Growth & Business Development Company Presentation | March 2025 16
Slide 17: Distribution Growth & Business Development
Biome Australia Distribution Growth & Business Development ● Biome has grown its Australian distribution al use only from 100 distribution points in 2019 to 6000 in 2025 - the total addressable distribution market for Biome in our local market is ~12,000. ● Existing distribution (6000) is expected t
Slide 18: IP Development
Biome Australia al use only 03. IP Development Company Presentation | March 2025 18
Slide 19: BMB18
Biome Australia BMB18 Biome has executed an agreement to develop a Biome owned novel al use only probiotic strain ● Lactobacillus plantarum BMB18 Biome has successfully completed the identification, commercial validation and initial characterisation of the probiotic strain Lactobacillus plantarum BMB
Slide 20: International Markets
Biome Australia al use only 05. International Markets Company Presentation | March 2025 2025 20
Slide 21: Canada — North America
Biome Australia Canada — North America International markets grow 95% to reach ~$895k in sales al use only revenue for FY24 ● Health Canada Approvals received in H2 FY24 (12/17 Activated Probiotics products) ● Test market launch successful with Ecotrend In Q1 FY25 ● First territory manager hired in
Slide 22: New Product Development
Biome Australia al use only 06. New Product Development Company Presentation | March 2025 22
Slide 23: The Microbiome Health Company
Biome Australia Group The Microbiome Health Company al use only Company Presentation | March 2025 23
Slide 24: Summary
Biome Australia Summary ● FY24 Sales Revenue $13.01m, up 80% ● FY25 Q1 pharmacy same stores sales up 68% (vs al use only PCP) ● Q2 FY25 Sales Revenue $4.6m (new record) ● Three ongoing clinical trials on key products ● Q2 $229,917 EBITDA adjusted for non-cash, share-based payments) ● Average shopper
Slide 25: Contact details
Biome Australia al use only Contact details Blair Norfolk, CEO Douglas Loh, CFO Email corporate@biomeaustralia.com Websites biomeaustralia.com activatedprobiotics.com.au Company Presentation | March 2025 25